Old Web
English
Sign In
Acemap
>
authorDetail
>
Pamela A. Trail
Pamela A. Trail
Bayer HealthCare Pharmaceuticals
Myeloid leukemia
Cell growth
Sorafenib
Leukemia
Tyrosine kinase
4
Papers
498
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Antitumor activity of sorafenib in FLT3-driven leukemic cells
2007
Leukemia
Daniel Auclair
D. Miller
V Yatsula
Walter Pickett
Christopher Carter
Yong S. Chang
Xiaomei Zhang
Dean Wilkie
A Burd
H. Shi
S Rocks
R Gedrich
L Abriola
H Vasavada
Mark Lynch
Jacques Dumas
Pamela A. Trail
Scott Wilhelm
Show All
Source
Cite
Save
Citations (141)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
2007
Cancer Chemotherapy and Pharmacology
Yong S. Chang
Jalila Adnane
Pamela A. Trail
Joan Levy
Arris Henderson
Dahai Xue
Elizabeth Bortolon
Marina Ichetovkin
Charles Chen
Angela McNabola
Dean Wilkie
Christopher Carter
Ian C. A. Taylor
Mark Lynch
Scott Wilhelm
Show All
Source
Cite
Save
Citations (357)
ORIGINAL ARTICLE Antitumor activity of sorafenib in FLT3-driven leukemic cells
2007
Daniel Auclair
D. Miller
V Yatsula
Walter Pickett
Christopher Carter
Yong S. Chang
Xiaomei Zhang
Dean Wilkie
A Burd
H. Shi
S Rocks
R Gedrich
L Abriola
H Vasavada
Mark Lynch
Jacques Dumas
Pamela A. Trail
Scott Wilhelm
Show All
Source
Cite
Save
Citations (0)
BAY 43-9006 (Sorafenib) is a potent inhibitor of FLT3 tyrosine kinase signaling and proliferation in AML cells
2005
Cancer Research
Daniel Auclair
Donna Miller
Christopher Carter
Yong Chang
Barbara Polony
Xiaomei Zhang
Victoria Yatsula
Walter Pickett
Timothy Housley
Amy Burd
Hong Shi
Sandy Rocks
Richard Gedrich
Laura Abriola
Don Apanovitch
Istvan Enyedy
Jacques Dumas
Bernd Riedl
Pamela A. Trail
Scott Wilhelm
Show All
Source
Cite
Save
Citations (0)
1